Adherence to the immunomodulatory drugs for multiple sclerosis: Contrasting factors affect stopping drug and missing doses

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 6, 2008, Pages 565-576

  Tremlett, Helen ^a   Van der Mei, Ingrid ^b   Pittas, Fotini ^b   Blizzard, Leigh ^b   Paley, Glenys ^b   Dwyer, Terence ^c   Taylor, Bruce ^d   Ponsonby, Anne Louise ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Adherence; Beta interferon; Compliance; Glatiramer acetate; Immunomodulatory treatment; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; IMMUNOLOGIC FACTOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; AUSTRALIA; COHORT ANALYSIS; DISEASE COURSE; DRUG MEGADOSE; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RELAPSE; UNSPECIFIED SIDE EFFECT; DRINKING BEHAVIOR; FORECASTING; MIDDLE AGED; PROSPECTIVE STUDY; QUESTIONNAIRE; RECURRENT DISEASE; STATISTICAL MODEL;

ADULT; AGED; ALCOHOL DRINKING; COHORT STUDIES; EDUCATIONAL STATUS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; IMMUNOLOGIC FACTORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECURRENCE; TASMANIA;

EID: 46349110053     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1593     Document Type: Article

References (41)

1. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26: 331-342.
2. World Health Organization. Adherence to Long-term Therapies: Evidence for Action. World Health Organization: Geneva, Switzerland, 2003.
3. Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J 2005; 81: 302-308.
4. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2004; DOI: 10.1002/ 14651858.CD004678
5. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001; DOI: 10.1002/14651858. CD002002
6. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-554.
7. Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003; 74: 1689-1692.
8. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005; 11: 46-50.
9. Mohr DC, Goodkin DE, Likosky W, et al., Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherenee to treatment. Mult Scler 1996; 2: 222-226.
10. Rio J, Porcel J, Tellez N, et al., Factors related with treatment adhereace to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-309.
11. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
12. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
13. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-1517.
14. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999; 53: 679-686.
15. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
16. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-1506.
17. Cocco E, Marchi P, Floris G, et al. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. Funct Neurol 2006; 21: 145-149.
18. Durelli L, Oggero A, Verdun E, et al. Interferon-beta dose and efficacy: the OPTIMS study. Neurol Sci 2001; 22: 201-203.
19. Barbero P, Verdun E, Bergui M, et al. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. J Neurol Sci 2004; 222: 13-19.
20. Gilbert J, Evans C, Haynes R, et al. Predicting compliance with a regimen of digoxin therapy in family practice. CMAJ 1980; 123:119-122.
21. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol 1983; 13: 227-231.
22. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
23. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
24. National Health and Medical Research Council, Canberra. Australian alcohol guidelines: health risks and benefits, 2001. Available at http://www.nhmrc.gov.au/publications/_files/ds9. pdf (Accessed 21 November 2006).
25. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
26. Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 2002; 52: 69-77.
27. Tombaugh TN. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch Clin Neuropsychol 2006; 21: 53-76.
28. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 1049-1060.
29. Rothman KJ. Modern Epidemiology. Little Brown & Co: Boston, MA, 1986; 150.
30. National Health and Medical Rcsearch Council, Canberra. Australian alcohol guidelines: health risks and benefits, 2001. Available at http://www.nhmrc.gov.au/publications/_files/ds9. pdf (Accessed 11 February 2008).
31. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
32. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288: 2880-2883.
33. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
34. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54: 531-533.
35. Mohr DC, Likosky W, Boudewyn AC, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998; 4: 487-489.
36. Stephenson B, Rowe B, Haynes R, et al. The rational clinical examinaaon. Is this patient taking the treatment as prescribed? JAMA 1993; 269: 2779-2781.
37. Bosworth HB, Oddone EZ, Weinberger M. Patient Treatment Adherence: Concepts, Interventions, and Measurement. Lawrence Erlbaum Associates, Publishers: Mahwah, NJ, 2006.
38. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-46.
39. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-1238.
40. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66: 172-177.
41. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.